There are 749 resources available
Outcome of the Consensus Conference on agnostic treatments
Presenter: Takayuki Yoshino
Session: ESMO – JSMO Collaborative Session: Guideline harmonisations and international consensus
Resources:
Slides
Webcast
Harmonisation and international consensus? Differences in evaluation of an agnostic approach between agencies (EMA, FDA, PMDA)
Presenter: Francesco Pignatti
Session: ESMO – JSMO Collaborative Session: Guideline harmonisations and international consensus
Resources:
Slides
Webcast
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer
Presenter: Kei Muro
Session: ESMO – JSMO Collaborative Session: Guideline harmonisations and international consensus
Resources:
Slides
Webcast
Overall survival with first-line durvalumab plus platinum-etoposide in patients with extensive-stage (ES)-SCLC in CASPIAN: Subgroup findings from Asia
Presenter: Makoto Nishio
Session: Proffered paper session - Thoracic cancers
Resources:
Slides
Webcast
Invited Discussant LBA15 and 474O
Presenter: Sanjay Popat
Session: Proffered paper session - Thoracic cancers
Resources:
Slides
Webcast
PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations
Presenter: Shahneen Sandhu
Session: Mini Oral session - Genitourinary tumours
Resources:
Slides
Webcast
Real-world assessment of clinical effectiveness and safety of pazopanib in patients with advanced or metastatic renal cell carcinoma (RCC) in Asia, North Africa and Middle East countries: A prospective, observational study (PARACHUTE)
Presenter: Ravindran Kanesvaran
Session: Mini Oral session - Genitourinary tumours
Resources:
Slides
Webcast
Discussion led by moderator
Presenter: Ben Tran
Session: Mini Oral session - Genitourinary tumours
Resources:
Slides
Is there a role of neoadjuvant chemotherapy? EORTC and Indian trial presentations
Presenter: Gemma Kenter
Session: Contemporary issues in cervical cancer management
Resources:
Slides
Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis
Presenter: Byoung Chul Cho
Session: Proffered paper session - Thoracic cancers
Resources:
Slides
Webcast